

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 October 2002 (17.10.2002)

PCT

(10) International Publication Number
WO 02/081662 A1


- (51) International Patent Classification⁷: C12N 5/00
- (21) International Application Number: PCT/US02/10411
- (22) International Filing Date: 2 April 2002 (02.04.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/281,268 3 April 2001 (03.04.2001) US
- (71) Applicant (for all designated States except US): **BIO-CEPT, INC.** [US/US]; 2151 Las Palmas Drive, Suite C, Carlsbad, CA 92009 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **HAHN, Soonkap** [KR/US]; 511 Via Delphin, San Clemente, CA 92672 (US). **FAGNANI, Roberto** [—/US]; 524-L Via de la Valle, Solana Beach, CA 92075 (US). **DONG, Xiaofan**

[US/US]; 1044 Agate Street, #8, San Diego, CA 92109 (US). **EDMAN, Carl, F.** [US/US]; 12545 El Camino Real, #C, San Diego, CA 92130 (US). **TSINBERG, Pavel** [US/US]; 5370 Toscan Way, H-118, San Diego, CA 92122 (US).

- (74) Agents: **SAMPLES, Kenneth, H.** et al.; Fitch, Even, Tabin & Flannery, Suite 1600, 120 South LaSalle Street, Chicago, IL 60603 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]


(54) Title: METHODS AND GEL COMPOSITIONS FOR ENCAPSULATING LIVING CELLS AND ORGANIC MOLECULES



X = Polyethyleneoxide or copolymer of polyethyleneoxide and polypropyleneoxide capped with polyisocyanates and lightly crosslinked with polyols

Y = Polyethyleneoxide or copolymer of polyethyleneoxide and polypropyleneoxide

Z = Polymer or monomer
W = Nucleophile such as amine, hydroxyl or like



Crosslinking between prepolymers (I and I or I and II) until all isocyanates are consumed.

(57) Abstract: A method for encapsulating biologics within a hydrogel by using an aqueous solution of an isocyanate-functional hydrogel prepolymer which is mixed with an amount of biologics and an aqueous solution containing a dithiol crosslinking agent under physiological pH conditions. An additional bidentate crosslinking agent may be included. The product of such method may be a bioreactor or an assay device having a plurality of different biologics encapsulated at predetermined locations in a substrate.



WO 02/081662 A1



Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments*

Published:

— *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

METHODS AND GEL COMPOSITIONS FOR ENCAPSULATING LIVING CELLS AND ORGANIC MOLECULES

This application claims priority from U.S. Provisional Patent Application Ser. No. 60/281,268, filed April 3, 2001, the disclosure of which is incorporated herein by reference.

Field of the Invention

5 The present invention relates to systems and methods for forming polyurethane hydrogels useful for encapsulating biologics, such as living cells, proteins, enzymes, antibodies and small organic molecules, and to the compositions which result therefrom. More specifically, the present invention relates to the formulation and use of a polymerization process employing biocompatible polymers
10 and biocompatible polymerization conditions, such as neutral pH, where there is maintenance of an aqueous environment and preservation of physiologically relevant osmolarity throughout the polymerization process, as well as to bioassays utilizing such improved resultant products. This invention represents a significant development in the art of encapsulation of certain materials and a significant
15 advancement, from certain standpoints, of the process described in U.S. Patent No. 6,174,683, which is assigned to the assignee of this application.

Description of Prior Art

The use of enzymes, antibodies, peptides, or other bioactive molecules, e.g. aptamers, has received increasing attention as tools for screening in the fields of
20 bioassays and proteomics. As part of this development, the use of hydrogel supports for these bioactive materials has also gained in importance. Hydrogels are defined as water-containing polymeric matrices. In particular, hydrogels provide a support for biomaterials that more closely resembles the native, aqueous, cellular environment, as opposed to a more denaturing environment that results when proteins or other
25 materials are directly attached to a solid support surface using other molecular scale linkages, such as coatings.

Certain hydrogels have previously been described as matrix supports for biomolecules and/or living cells, and these include alginates, alginates modified to permit cross-linking, acrylamide-based hydrogels, and polyethylene oxide-based

hydrogels. In general, however, there is frequently difficulty in reconciling the gel polymerization and encapsulation requirements with the gentle conditions requisite for maintaining the viability or activity of live cells or certain active proteins. In addition, many of the materials suitable for these gentle conditions, e.g. alginate-based
5 polymers, lack the structural requirements and/or biostability necessary for broad applications.

Alginate gels have been widely utilized for immobilization of eukaryotic cells and proteins. This form of hydrogel is generally benign and biocompatible during the encapsulation process; however, it can suffer from a lack of structural stability.

10 Alginates are thus sometimes combined with multivalent cations to form more stable, ionically cross-linked gels. However, upon exposure to physiologically relevant buffers and environments, divalent cations tend to exchange with monovalent species, and the polymer often loses structural integrity. As a result, alginates are somewhat undesirable hydrogels for encapsulating biomolecules and living cells. Moreover, the
15 overall manufacturability of alginate gels is difficult, further lessening the desirability and applicability of such a gel system.

Polyacrylamide hydrogel systems have also received considerable attention as matrices for attaching biomolecules and encapsulation vehicles. For example, Arenkov, et al. (Anal. Biochem. 278, 123-131 (2000)), describe gel pad arrays formed
20 by photoinitiated polymerization of acrylamide/bisacrylamide mixtures using methylene blue as the photocatalyst. Proteins are then covalently linked to each gel pad following application to the micromatrix either by crosslinking with glutaraldehyde or by chemical modification of carbohydrate moieties present on select
proteins to allow subsequent chemical linkage to the gel support. However, such a
25 method of linkage can be potentially very damaging to the integrity and/or activity of the protein, and it may also require the presence of sugar residues not ubiquitously found on all proteins.

Alternative to the use of polyacrylamide-based hydrogels are the use of those composed primarily of polyethylene oxide (PEO) polymerization units. These
30 polymers can offer a number of distinct advantages in the areas of biocompatibility, diffusion of small molecules and manufacturing process control. For example, the grafting of PEO onto serum albumin significantly reduces immunogenicity of the native albumin (Abuchowski, et al. 1977). Hubbell, et al. (U.S. Patent No. 5,573,934

and related patents) teach the use of polyethylene glycol polymers for encapsulating cells using a dye-based photoinitiated free radical-based polymerization process.

In the aforementioned polyacrylamide or PEG polymeric gels, initiation of polymerization requires the addition of a separate, photoactivatable catalyst and/or the
5 addition of free radical-generating polymerization accelerators, separate and distinct from the polymer components or subunits. Chudzik and Anderson (U.S. Patent No. 6,156,345) teach the use of polymer initiator groups which are pendant from the polymerizable groups and thus avoid the separate addition of initiator components.

Mixed polymer/alginate systems have also been devised to overcome
10 limitations inherent in each system alone. For instance, Desai, et al. (U.S. Patent No. 5,334,640) employ mixtures of an ionically cross-linked biocompatible component with a covalently linked component. However, the overall process remains dependent upon photoinitiated, free radical-based polymerization.

Use of methodologies incorporating free radicals as essential elements within
15 such a process is a generally undesirable feature of many of the encapsulation/polymerization techniques in present use. For example, in cell encapsulation with acrylamide gels, "polymerization of acrylamide generates heat and free radicals, causing loss of in the chemiosmotic integrity and enzymatic activity of the immobilized cells" (see Poncelet De Smet, et al. in "Fundamentals of Animal Cell
20 Encapsulation and Immobilization", Mattheus F.A. Goosen , editor, CRC Press, Boca Raton, FL, 1993, p. 301). It is therefore desirable to provide a polymerization process which does not use free radicals to initiate polymerization, thereby avoiding potential harm to encapsulated cells and biomolecules. It is also desirable to utilize polymers
25 particularly ones which are truly biocompatible, i.e. non-toxic to the encapsulated biomolecule or cell and to the surrounding media or host.

Wood, et al. teach the use of various cross-linking polymer systems, including a polyurethane-based hydrogel formed from isocyanate-functional prepolymers, to form a cross-linked polymer to encapsulate microbial cells (U.S. Patent Nos.
30 4,436,813 and 4,732,851). Also described are methods using polyazetidine prepolymers and carboxymethylcellulose which can be crosslinked with polyvalent ions. Direct contact of isocyanates with the microbial cells which occurs in the encapsulation within such a polyurethane-based hydrogel and exposure to other

potentially toxic conditions may not be suitable for the encapsulation of certain sensitive biological materials.

In the '683 patent, a polyurethane-based hydrogel prepolymer is used to simultaneously derivatize biomolecules, such as nucleic acid probes, within its structure during polymerization. Such a polymerization process can use PEG-based prepolymers and is advantageous from its avoidance of free radicals or other agents as a result of its employ of water to initiate polymerization. However, because organic solvents are often employed in the prepolymer formation, derivitization and/or solubilization, the process may still be toxic to certain sensitive biological materials, such as living mammalian cells.

In brief, there remains a particular need for truly benign, non-toxic, biocompatible and mechanically robust hydrogel polymers and associated polymerization methodology in order to encapsulate certain biologics, such as sensitive proteins, enzymes, antibodies and living cells, in a useful and economically feasible fashion, which can provide products that are well suited for assays and other applications.

Summary of the Invention

It is an object of the invention to provide a method for biocompatible polymerization of isocyanate-modified biocompatible macromers to either directly or indirectly encapsulate or coat biologics, i.e. living cells, proteins, nucleic acids and other bioactive materials and compounds, including small organic molecules. The polymerization process is truly biocompatible as it employs no organic solvents. This novel process utilizes thiol-based crosslinkers which reduces the crosslinking of biomaterials within the hydrogel, thereby rendering the process capable of encapsulating and attaching such biological material in forms particularly suitable for diagnostic and therapeutic use, for example, microarrays of proteins or cells or other organic compounds for high-throughput testing.

The method of polymerization employs thiol-containing crosslinkers and selective reaction conditions, specifically neutral pH and aqueous buffers, to preferentially favor the reaction of sulfhydryl groups, as opposed to amines, as the preferred conjugation nucleophile where water is present during polymerization; this provides mild, non-radical reaction conditions that allow gentle encapsulation which is of particular importance to biomolecules and living cells. The porosity of the

encapsulating polymer can be advantageously varied, and the encapsulation process permits deposition, onto glass slides or other surfaces, of discrete hydrogel droplets in spots or layers that encapsulate cells, proteins or other organic molecules, either directly or indirectly through binding agents, or alternatively by forming droplets or
5 spheres that separately encapsulate such biologics. Moreover, the overall encapsulation/ polymerization process comprises fewer steps than comparable methodologies, thereby simplifying and easing process development. Because the resultant polymers can provide antibody or enzymatic arrays and viable cell encapsulation, the potential employment of such materials in bioreactors, biosensors,
10 biochips and artificial organs is facilitated. Such encapsulated cells are expected to serve as a logical extension of bioassay development for complex biopathway screening, and encapsulated cells will be useful tools in bioreactors for economically generating complex therapeutic agents and materials. In addition, encapsulated living cells may potentially serve as artificial organs or biosensors, responding as needed to
15 altered or toxic environments. Microarrays of encapsulated cells or other such biologics are also expected to be useful in high throughput biological testing.

Brief Description of the Drawings

FIG. 1 is a diagrammatic view showing a mechanism of cross-linking prepolymers.

20 FIG. 2 is a diagrammatic view, similar to FIG. 1, of an alternative cross-linking reaction embodying various features of the present invention.

Detailed Description of the Preferred Embodiments

Water is often added to cure or initiate the crosslinking of isocyanate-functional prepolymers. This is in contrast to processes employing free radical-based
25 methodology, e.g. UV-induced photopolymerization, that is used to generate reactive species suitable for forming covalent linkages between prepolymer units. Isocyanate-functional groups are covalently linked to a prepolymer of choice, and such addition of water produces an active primary amine at a certain frequency by conversion of some isocyanate moieties, based upon temperature and pH. Such primary amines
30 subsequently react with other isocyanates attached to other prepolymer units, thereby covalently linking the prepolymer units together, as illustrated in FIG. 1; this is generally representative of certain reactions utilized in the '683 patent. This process leads to the generation of an optically transparent, urea-based hydrogel, so long as

reactivity of the prepolymer and reaction conditions are controlled to prevent gas bubble formation and/or precipitation of the polymer. During such a polymerization process, various biological entities or small molecules, i.e. biologics, can be present or can be added to create biologically active hydrogels. The term biologics, for purposes
5 of this patent application, should be understood to include living cells, proteins, such as antibodies, other bioactive materials, both natural or synthetic, and small organic molecules which function bioactively. It can thus be seen that the size of a biologic may vary substantially and, as explained hereinafter, molecules of small size may desirably be provided with anchoring moieties.

10 The '683 patent describes the addition of primary amine-derivatized oligonucleotides to isocyanate-functional prepolymers in order to produce oligonucleotide arrays that are attached to a solid support surface. An advantageous feature of such a process is that, during the completion of the polymerization reaction between isocyanate prepolymer units, the oligonucleotides will become covalently
15 linked to the polymer matrix. However, such a method, based upon amine conjugation, may not be suitable for certain sensitive biologics, e.g. certain proteins and living cells. Because primary amines are components of all proteins including those present on the surface of living cells, e.g. ligand receptor proteins, ion channel proteins and cell-to-cell adhesion proteins, extensive derivatization or conjugation of
20 such amines directly to the isocyanate-functional prepolymer may lead to the protein's inactivation, denaturation or altered functionality. It has now been found that this possibility is minimized as a result of employing a new crosslinking approach that relies primarily upon thiol groups, instead of amines, for this purpose.

Thiol-based crosslinking agents serve as mediators of the cross-linking
25 reaction between isocyanate groups on different prepolymers, as opposed to employing amine functionalities. Of course, in an aqueous environment, a certain percentage of the isocyanate groups will undergo hydrolysis; however, the primary amines formed as a result will have pKa values in the range of 9 to 10. By maintaining a neutral pH, the vast majority of these amines will be protonated and
30 therefore will not participate in the polymerization process. As a neutral pH, 6.5 to 7.5 is preferred, 6.6 to 7.1 is more preferred and approximately pH 7.0 is most preferred. The presence of such thiol-containing species will cross-link unreacted isocyanate groups so as to effectively carry out the polymerization process.

One advantageous result of such preferential use of thiol crosslinkers is the minimization of reactions with the biologics being encapsulated or immobilized at locations on the molecule where attachment to the matrix is undesirable. Control of the pH of the polymerization reaction, which places a restraint upon the nucleophilic reactivity of the amines but not the thiol groups, avoids creation of extensive links to proteins within the matrix. Proteins are of course composed of a variety of amino acids, some of which contain side chain primary amines that are potentially reactive during the overall polymerization process. However, linking to such amine functionalities may well hinder the natural movement and conformation of the proteins, and in the case of living cells, it will likely alter the pattern and responsiveness of extracellular and plasma membrane proteins. The present method avoids or substantially limits occurrence of such links and the negative aspects thereof.

For example, the pKa value for the side chain primary amine of the amino acid lysine is quite basic, approximately 10.5, and that for arginine is even more basic, i.e. over 12. If the pH of the polymerization mixture is maintained approximately neutral, then the proportion of free amine suitable for participating in a nucleophilic addition, such as that shown in FIG. 1, is less than 1/1000th of the total primary amine population represented by lysine side chains. In contrast, thiol groups remain nucleophilic and very reactive at neutral pH values. Although cysteine residues in proteins contain a thiol side chain, the frequency of cysteines within proteins is generally more than 3-fold lower than that of lysine, and when present, cysteines are frequently oxidized so as to form intramolecular cystine linkages in native proteins, thereby further lowering the number of available sulfhydryl groups. The overall result is a very substantial reduction in the number of multiple, potentially denaturing links between embedded proteins or cells and the polymer matrix; thus, such thiol-mediated crosslinking of hydrogel prepolymers provides improved formulations for encapsulating sensitive biological molecules and living cells.

In addition, this encapsulation method, which depends upon thiol reactions, also provides a very effective way of anchoring small organic molecules, for example organic molecules having a molecular weight between 100 and 2000 and particularly those having a molecular weight not greater than about 500, in a manner so that they fully retain their effectiveness in the hydrogel. These small molecules are derivatized to place a thiol group at a location in the molecule where it will not interfere with the

secondary or tertiary configuration of the small molecule, for example, at one end of a generally linear molecule. Although the small molecule might be of such a size that it would not necessarily be retained in an encapsulating matrix of this type, the presence of the thiol group will result in a linking to an isocyanate group on the polymer and
5 thus anchor the small organic molecule within or upon the gel in a manner such that it can assume its normal active configuration. In this manner, the encapsulation method can be used to create what might be termed chemical chips, as well as protein chips, cellular chips and the like.

Isocyanate-functional prepolymers are often prepared from relatively high
10 molecular weight polyoxyalkylene diols or polyols that are reacted with difunctional or polyfunctional isocyanate compounds. Preferred prepolymers are ones made from polyoxyalkylene diols or polyols that comprise homopolymers of ethylene oxide units or block or random copolymers containing mixtures of ethylene oxide units and propylene oxide or butylene oxide units. In the case of such block or random
15 copolymers, at least 75% of the units are preferably ethylene oxide units. Such polyoxyalkylene diol or polyol molecular weight is preferably from 2,000 to 30,000 and more preferably from 5,000 to 30,000. Suitable prepolymers may be prepared by reacting selected polyoxyalkylene diols or polyols with polyisocyanate, at an isocyanate-to-hydroxyl ratio of about 1.2 to about 2.2, so that essentially all of the
20 hydroxyl groups are capped with polyisocyanate. Aliphatic, rather than aromatic isocyanates, are preferred as they provide more easily controlled polymerization. Generally, polyethylene glycol (PEG), polypropylene glycol (PPG) or copolymers thereof are preferred. The isocyanate-functional prepolymers being used preferably contain active isocyanates in an amount of about 0.1 meq/g to about 1 meq/g, and
25 more preferably about 0.2 meq/g to about 0.8 meq/g. Should relatively low molecular weight prepolymers, e.g. less than 2,000, be used, they preferably contain a relatively high isocyanate content (about 1 meq/g or even higher). However, the polymerization rate of such smaller prepolymers may require more precise control to avoid too rapid polymerization, and thus would be less preferred for fabricating microarrays and the
30 like. Moreover, prepolymers with a fairly high isocyanate content may have a relatively high content of free amines after polymerization, and the positive charges on such amine functionalities, at neutral pH, may increase non-specific binding of negatively charged biomolecules with the potential of resulting in higher levels of

undesirable background signals. Thus, higher molecular weight prepolymers which contain a relatively low isocyanate content are preferred.

In order to enhance the diffusability of large biological molecules, it may be desirable to use low ratios of prepolymer (3 – 5%) relative to the total volume of the ultimate formulation. Such relatively low percentages aid in producing hydrogel compositions having the desired porosity for use in assays, bioreactors and the like. As mentioned above, the viability of entrapped biological molecules is enhanced through minimization of the involvement of amine groups by employing crosslinkers with thiol functions and maintaining a physiological pH of about 7.0, where a large percent of amines ($pK_a = \sim 10$) will be present as protonated species which do not react with the isocyanate functionalities. Although such an arrangement in some instances could potentially result in incomplete curing of the prepolymer, the nucleophilic activity of thiols towards isocyanates is unaffected at such pH so curing can be completed, and the overall result is one of a significant advancement in formulating PEG and/or PPG-based hydrogels for encapsulating biomaterials.

Short-chain dithiol crosslinkers, such as 1,4-dithiothreitol ($mw = 154$), produce a fairly high speed polymerization that needs to be slowed and carefully controlled to avoid precipitation. Longer dithiol crosslinkers provide formulations for hydrogel polymerization that are more easily controlled. Crosslinkers having a backbone of PEG and/or PPG units are one class of dithiols that provide biocompatibility and structural advantages, and such crosslinkers of molecular weight between about 500 and 10,000 are preferred, with those between about 2,000 and 6,000 being more preferred and those between about 3,000 and 4,000 being most preferred. For example, PEG-(thiol)₂ (Shearwater Polymers, Inc.) having a $mw = 3,400$ and thiol groups at the ends of the chains, may be used with Hypol PreMa G-50 (Hampshire Chemical Corp., which has an aliphatic isocyanate content of ~ 0.35 meq/g), and by varying the ratio between two such starting materials, it was found that the speed of polymerization can generally be effectively controlled at pH 7.0. The molar ratio of dithiol crosslinker to isocyanate (from the prepolymer) is preferably not higher than about 0.3 dithiol per isocyanate, and more preferably not higher than about 0.2 dithiol per isocyanate.

Formulations having a ratio significantly lower than 0.1 dithiol per isocyanate, e.g. 0.05 or below, might not polymerize promptly and/or completely at pH 7.0 without the inclusion of an auxiliary crosslinker. Thus, formulations having a ratio

slightly less than about 0.1 dithiol per isocyanate are preferably supplied with an auxiliary bidentate crosslinker having two different isocyanate-reactive functional groups, one of which is preferably thiol, e.g. cysteine which has a side chain thiol group and a less reactive primary α -amine group which is of course more nucleophilic than the α -carboxyl under these conditions. Other bidentate crosslinkers that might be used include 2-mercaptoethanol, 2-aminoethanethiol, homocysteine, 2-mercaptopropanol and other short chain compounds having a thiol group and another nucleophilic group. Moreover, even when an adequate amount of the dithiol crosslinker is provided, it has been found that the provision of an auxiliary bidentate crosslinker can be advantageous in controlling the polymerization reaction in obtaining completion within desirable time limits and in obtaining hydrogel compositions that are stable, have a high water content and excellent structural strength. Accordingly, the employment of the combination of a dithiol crosslinker of relatively high molecular weight, e.g. about 2,000 to 6,000 mw, and a bidentate crosslinker of much lower molecular weight, preferably below about 300 mw, is preferred. It was found that this addition of a moderating bidentate crosslinker having two different reactive groups (e.g. cysteine) provides a novel and powerful means by which polymerization can be effectively controlled, and such is diagrammatically illustrated in FIG. 2, which also indicates that crosslinking in this manner eliminates a large amount of CO₂ that would otherwise be created in normal crosslinking. When such an auxiliary crosslinker is used, it is generally used in a molar amount from about 1 to 3 times the molar amount of the dithiol, and preferably from about 1.5 to about 2.5 times the moles of the dithiol crosslinker, in which amount it has been found to moderate the polymerization reaction and result in satisfactory curing.

The inherent reactivity of prepolymers of this general type allows the use of chemically functional surfaces to also achieve covalent attachment of the polymer to a substrate during polymerization. Such surfaces may be provided upon substrates which will facilitate the handling and instrumented examination of the polymerized hydrogel and encapsulated biological matter; for example, fabrication of a microarray containing different bioactive material encapsulated into individual spots or regions of polymerized hydrogel placed in a known pattern on such a substrate.

Neutral pH is preferably maintained throughout the polymerization process by the use of 50 mM phosphate buffer supplemented with NaCl, typically 10 mM to 80 mM; osmotic pressure is preferably maintained at physiological levels, approximately

300 milliosmoles. It is found that such formulations can be made without using organic solvents by mixing isocyanate-derivatized prepolymers rapidly in phosphate buffer/NaCl and then rapidly adding a premixed solution of cells or proteins and dithiol crosslinker in phosphate buffer/NaCl. The polymerization process will then
5 generally occur within 20 to 60 minutes, typically less than 30 minutes, during which time the cells or proteins remain in a hydrated and an osmotically balanced state at physiological pH. Preferably, pH and osmolality are maintained between 6.9 to 7.6 and between 250 to 400 mOsm/kg, respectively. Once cured, polymer sites containing the encapsulated biologics are easily washed, and manipulated.

10 Optical examination of these thiol-crosslinked hydrogels reveals optical clarity with no background fluorescence attributable to the gel formulation and generally similar optical properties to hydrogel formulations described in the '683 patent. However, in the '683 processes, it was often very important to carefully control the rate of CO₂ evolution to avoid some opacity. The present process which uses dithiol
15 crosslinkers in combination with bidentate modifiers inherently minimizes CO₂ evolution, as mentioned before with respect to FIG. 2, and can produce an optically transparent hydrogel with essentially no difficulty.

To show that these polyurethane hydrogels are suitable for encapsulating a wide range of biologics, encapsulation of living eukaryotic cells was first examined.
20 One criteria for the success of encapsulation of living cells is an assessment of continued cell viability, and typically, trypan blue exclusion is a technique frequently favored by biologists to easily determine cell viability. However, because the hydrogel absorbs a significant amount of the trypan blue dye, determination of cell color and intensity of the intracellular dye using this method was unreliable. As an
25 alternative, AlamarBlue™ (Trek Diagnostic Systems, Inc.) was used. AlamarBlue is a dye that becomes fluorescent upon reduction by metabolic processes. Goat lymphocytes, having been determined by trypan blue exclusion to have both viable and dead cells present within the cell mixture, were chosen, and the prepolymer and cell suspension/dithiol crosslinker/bidentate crosslinker were mixed. The
30 lymphocytes became encapsulated within the thiol-crosslinked hydrogel when droplets of the mixture were deposited as spots (approximately 300 – 1,000 microns in diameter, with a height equal to or greater than 20 microns) upon glass slides and then cured in a high humidity chamber at room temperature; mixing and curing took just less than 20 minutes. Preferably, the relative humidity (RH) is at least about 90%

and more preferably is about 95% or higher. With the spots firmly attached to the glass slide, the slide was incubated for three hours at 37° with RPM 1640 media followed by incubation for 1.5 hours with AlamarBlue™ dye that had been mixed one part to twenty with RPM1640 media. After leaving the slide for 30 minutes in the dark, visualization of the spots using an epifluorescence microscope revealed brightly stained individual cells against a moderately fluorescent hydrogel background. Visible light revealed cells within the gel which were not brightly stained, which were presumably the aforementioned dead cells already present within the cell suspension. Hydrogel-only spots treated in an analogous fashion had no visible fluorescence. Therefore, AlamarBlue™ is felt to be a useful tool for accessing cell viability within these polyurethane-PEG hydrogels, and the hydrogel itself and the polymerization process were shown to be biocompatible by the maintenance of viable cells.

Encapsulation of proteins was also examined, formulating the gel essentially as just described. Protein encapsulation was demonstrated by the sequestration/encapsulation of anti-transferrin antibody within the gel matrix during polymerization. Verification of the antibody's functionality was demonstrated by the specific binding of fluorescent dye-labeled transferrin to those sites containing the anti-transferrin antibody and not at other sites containing different antibodies or no antibodies.

As additional embodiments, encapsulated living cells and/or proteins within such a thiol-crosslinked hydrogel might be deposited as spots or regions upon support surfaces, such as glass slides, or within microwells or microchambers, such as would be present in standard 96 well, 384 well or 1536 well microtiter plates. Distinct advantages are present with both approaches. In depositing a number of discrete spots upon a single surface, each spot might contain a different entity, allowing a single incubation followed by the supply of wash solutions to contact all spots simultaneously. The use of individual microchambers would allow robotic handling of the plates and permit the use of low volumes of individual test solutions at each well. Combinations of these two approaches may also be used whereby individual chambers, arranged in a standard 96 well array or similar format, are each supplied with one or more hydrogel spots containing different entities.

Devices employing such arrays might be employed as combinatorial chemical or drug screening devices, antibody arrays, peptide arrays, cell arrays, enzymatic activity arrays, or DNA or other polynucleotide arrays that will be selective for binding to related proteins or other biomolecules. In addition, encapsulated cells or

biomolecules coated onto the walls of microcapillary tubes will function as flow-through devices having single or multiple channels, which might be employed as screening devices or as biosensors on systems, such as in liquid chromatography or in "lab-on-a-chip" devices. Signal readout from such devices might be via binding of
5 fluorescent proteins or of antigens, to be measured by subsequent antibody-based detection methods (possibly employing additional arrays), or via reaction with endogenous biopathways which will result in the formation of a detectable species, e.g. enzymatic conversion of a substrate to a fluorescent dye molecule, or change in the electrical properties, e.g. conductivity, of the cell and/or surrounding matrix
10 resulting from exposure to the specific agent. In particular, the addition of either a redox agent to the gel or the addition of an electrically conductive polymer may enable signal detection by electrical, non-photonics, means.

The working examples which follow include the best mode presently known for providing formulations and encapsulation methods embodying particular features
15 of the invention; however, they should be understood not to constitute limitations upon the scope of the invention which is of course defined by the claims that are set forth hereinafter.

Example 1

Solution A was prepared by mixing 0.075 g of Hypol PreMa G-50 (Hampshire
20 Chemical Corp.) and 1.5 mL of 50 mM aqueous phosphate buffer, at pH 7.0 with 80 mM sodium chloride. Solution B was prepared by dissolving 30 mg of PEG-(thiol)₂ (mw = 3,400) and 2 mg of free base cysteine (Sigma Chemical Co.) (mw = 121) in 1 mL of 50 mM phosphate buffer, at pH 7.0 with 60 mM sodium chloride. Solution C was prepared by mixing 100 µL of Solution B with 10 µL of goat lymphocytes in
25 Dulbecco's phosphate-buffered saline. Finally, 200 µL of Solution A was mixed with 50 µL of Solution C, and the resulting solution was microspotted onto amine-treated glass (Silanated Slides, Cell Associates, Inc.) with the use of 5 microliter glass microcapillary tubes. The hydrogel spots were polymerized carefully in a humidity box, at about 95% RH, to avoid dehydration. This formulation polymerized within
30 5–10 minutes. After polymerization, the hydrogel spots were physically stable and strongly attached to the glass slide; they were immediately treated with Dulbecco's modified phosphate-buffered saline solution and incubated at either room temperature or at 37° for about 3 hours in RPM1640 cell media. The viability of lymphocytes was

examined by means of the AlamarBlue staining method described previously. They were incubated for 1.5 hours with RPM1640 media plus the dye and then examined with a light microscope; viable, encapsulated cells were observed.

Example 2

5 Solution A was prepared by mixing 0.1 g of Hypol PreMa G-50 (Hampshire Chemical Corp.) and 1 mL of 50 mM phosphate buffer, at pH 7.0 with 80 mM sodium chloride. Solution B was prepared by the same procedure as in Example 1. Solution C was prepared by mixing 40 μ L of Solution B with 70 μ L of goat lymphocytes in Dulbecco's phosphate-buffered saline. Finally, 100 μ L of Solution A was mixed with
10 100 μ L of Solution C, and the resulting solution was microspotted using the same procedure as in Example 1. The formulation polymerized in 5 minutes, and the hydrogel spots were treated with Dulbecco's modified phosphate-buffered saline solution and incubated at 37°C for 1 day to 3 days in RPM1640 cell media. The viability of lymphocytes was examined with a light microscope using AlamarBlue
15 which demonstrated viable encapsulated cells.

Example 3

Solution A was prepared by mixing 0.1 g of Hypol PreMa G-50 (Hampshire Chemical Corp.) and 1 mL of 50 mM phosphate buffer, at pH 7.0 with 80 mM sodium chloride. Solution B was prepared by the same procedure as in Example 1. Solution
20 C was prepared by mixing 40 μ L of Solution B with 70 μ L of *E. coli* in Dulbecco's phosphate-buffered saline. Finally, 100 μ L of Solution A was mixed with 100 μ L of Solution C, and the resulting solution was placed into a disposable culture tube. The formulation polymerized in 5 minutes, and the hydrogel was treated with Dulbecco's modified phosphate-buffered saline solution and incubated at 37°C for 1 day in
25 RPM1640 cell media. Viability and growth of *E. coli* were confirmed by observing turbidity in the hydrogel after 1 day.

Example 4

Solution A was prepared by mixing 0.1 g of Hypol PreMa G-50 (Hampshire Chemical Corp.) and 1 mL of 50 mM phosphate buffer, at pH 7.0 with 80 mM sodium
30 chloride. Solution B was prepared by dissolving 30 mg of PEG-(thiol)₂ (mw = 3,400)

and 2 mg of free base cysteine in 1 mL of 50 mM phosphate buffer, at pH 7.0 with 60 mM sodium chloride. 25 μ L of Solution A, 10 μ L of Solution B, 5 μ L of 50 % trehalose in DI water and 10 μ L of anti-transferrin antibody (goat anti-human transferrin, 5 mg/ml, protein-G purified)(Calbiochem) were mixed, and the resulting solution was microspotted onto an amine-treated glass slide so as to form spots 300 μ m to 1,000 μ m in diameter and at least 20 μ m in height. Other similar spots were created without the addition of the anti-transferrin antibody. The hydrogel spots were carefully polymerized in a humidity box at room temperature and 95% RH, and after polymerization, the hydrogel spots were found to be physically stable and well attached to the glass slide. The slide was treated with a PBS buffer containing 1 % Bovine Serum Albumin (Sigma Chemical Co.) and 0.1 % Triton X-100 (Boehringer Mannheim) for 1 hour at room temperature. Anti-transferrin in the hydrogel was interacted with Cy3-labeled transferrin (1 μ g/ml in 1% bovine serum albumin, 0.1% triton X-100 in phosphate buffered saline) for 1 hour and then visualized; it demonstrated that there was specific binding of fluorescent dye-labeled transferrin at sites containing the anti-transferrin antibody and not at other sites containing different antibodies or no antibodies.

Example 5

Solution A was prepared by mixing 0.1 g of Hypol PreMa G-50 (Hampshire Chemical Corp.) and 1 mL of 50 mM phosphate buffer at pH 7.0. Solution B without salts was prepared by the same procedure as in Example 1. Solution C was prepared by mixing 40 μ L of Solution B with 70 μ L of 234 μ m L-alpha-cysteine-N-[8-(1,2,3,4-tetrahydro-acridin-9-ylamino)-octyl]-amide (mw = 428.26), an acetylcholine esterase inhibitor, in 50 mM phosphate buffer at pH 7.0. Finally, 100 μ L of Solution A was mixed with 100 μ L of Solution C, and the resulting solution was microspotted using the same procedure as in Example 1. The formulation polymerized in 5 minutes, and the hydrogel microspots were treated with cy-3 labeled acetylcholine esterase. This testing confirmed presence and functionality of acetylcholine esterase inhibitor in the hydrogel.

Although the invention has been described with regard to certain preferred embodiments, it should be understood that changes and modifications as would be

obvious to those having ordinary skill in this art may be made without deviating from the scope of the invention which is set forth in the claims appended hereto. The inclusion of additional polymers or modifications to the above-described polymer might permit either cell proliferation or increased viability of select cell types within
5 the matrix. For example, peptide linkages within such a polymer may be specifically crafted to dissolve upon exposure to extracellular matrix proteases generated by the encapsulated cell, thereby dissolving the polymeric matrix as needed to permit cell expansion and growth. Alternatively, other polymers or agents, such as collagen, might be added to such a polymeric blend to aid cell viability by use of specific
10 adhesion factors and/or binding methods between encapsulated cells and surrounding support. In contrast to spotting the hydrogel compositions onto a solid surface, hydrogel microbeads may be formed which encapsulate biologics. As one example, after mixing the prepolymer with the crosslinker and biologics, the polymer/cell (or protein) mix is added to a non-miscible liquid, such as an oil, while curing is
15 occurring to cause microbeads of various dimensions to be formed. Separation from the oil or other suspending liquid yields a slurry of beads suitable for use in bioreactors, assay devices, artificial organs, biosensors or the like. Moreover, multiple layers of encapsulated cells, proteins or other bioactive molecules might be used to construct complex materials having unique overall properties. Alternatively,
20 dyes or other agents might be added to the encapsulating polymer to facilitate subsequent identification of the encapsulated cell type if heterogeneous mixtures of cells are to be employed. Such a cell identification mechanism, combined with a chromophore-based or fluorescent-based response from specific cells in response to added agents, e.g. expression of green fluorescent protein in response to specific cell
25 signaling pathway activation by a ligand or drug, permits the screening of large populations of heterogeneous cells in a rapid and facile fashion.

The disclosures of all U.S. patents mentioned hereinbefore are incorporated herein by reference. Particular features of the invention are set forth in the claims which follow.

CLAIMS:

1. A hydrogel polymerization system for the encapsulation of biologics comprising:
 - (a) an aqueous solution of polyethylene glycol, polypropylene glycol, or a copolymer thereof, having isocyanate endgroups,
 - (b) an aqueous solution of a thiol-functional crosslinking agent,and
 - (c) a quantity of biologics for solution or suspension in solution (a) or (b).
2. The hydrogel polymerization system of claim 1 wherein the thiol-functional crosslinking agent comprises a thiol-functional crosslinking agent and a bidentate crosslinking agent having one thiol group and another different isocyanate-reactive group.
3. The hydrogel polymerization system of claim 2 wherein the bidentate crosslinking agent comprises cysteine.
4. The hydrogel composition of claim 1 wherein said biologics are selected from the group consisting of proteins, nucleic acids, living cells, and organic molecules having a molecular weight between 100 and 2000.
5. The hydrogel composition of claim 1 wherein said thiol-functional crosslinking agent comprises a backbone of polyethylene glycol, polypropylene glycol, or a copolymer thereof and has a molecular weight between about 2,000 and about 6,000.
6. A hydrogel biologic composition comprising:
 - (a) polyethylene glycol, polypropylene glycol, or a copolymer thereof which contains thio-urethane groups that form isocyanate-thiol crosslinks that provide a stabilized hydrogel, and
 - (b) a biologic which is bioactive encapsulated within said stabilized hydrogel.
7. The hydrogel composition of claim 6 wherein said stabilized hydrogel is optically transparent.
8. The hydrogel composition of claim 6 wherein said biologic is selected from the group consisting of proteins, nucleic acids, living cells, and organic molecules having a molecular weight between 100 and 2000.

9. The hydrogel composition of claim 6 wherein said biologic is an antibody.
10. A biochip wherein the hydrogel composition of claim 6 is formed as a plurality of discrete spots attached to a substrate.
11. The biochip of claim 10 wherein said spots are spatially arranged to form an array.
12. The biochip of claim 11 wherein the plurality of spots include some which contain at least two different biologics at known locations within said array.
13. A method of encapsulating biologics within a hydrogel comprising:
 - (a) providing an aqueous solution of an isocyanate-functional hydrogel prepolymer;
 - (b) providing an amount of biologics;
 - (c) providing an aqueous solution containing a thiol crosslinking agent having at least two thiol groups;
 - (d) mixing said solutions and said biologics to initiate polymerization under physiological conditions of pH and ionic strength and create a polymerizing hydrogel; and
 - (e) dispensing said polymerizing hydrogel into a desired physical form.
14. The method of claim 13 wherein said amount of biologics is mixed with the solution of thiol crosslinking agent prior to mixing with said prepolymer solution.
15. The method of claim 13 wherein the thiol crosslinking agent comprises a backbone of polyethylene glycol, polypropylene glycol, or a copolymer thereof and has a molecular weight between about 2,000 and about 6,000.
16. The method of claim 13 wherein the crosslinking agent solution additionally comprises a bidentate crosslinking agent having one thiol group and another different isocyanate-reactive group.
17. The method of claim 16 wherein the bidentate crosslinking agent comprises cysteine or homocysteine.
18. The method of claim 13 wherein the polymerizing hydrogel is dispensed onto a solid substrate so as to result in attachment thereto of the hydrogel-encapsulated biologics.

19. The method of claim 13 wherein the polymerizing hydrogel is repeatedly dispensed onto multiple, pre-identified areas of a substrate to form discrete spots arranged as an array.

20. The method of claim 19 wherein different of said spots at known locations contain at least two different biologics.

21. The method of claim 13 wherein the biologics contain thiol-reactive groups for immobilization thereof to the polymerizing hydrogel.

22. A bioassay comprising the steps of:

(a) providing a biochip which comprises a substrate having a hydrogel composition bound thereto in at least two different regions, each region having a thickness of at least 20 micrometers and comprising polymers selected from the group consisting of polyethylene glycol, polypropylene glycol and copolymers thereof, characterized in that said hydrogel composition contains thio-urethane groups formed as a part of crosslinks between said polymers as a result of reaction with crosslinkers that undergo isocyanate-thiol reactions, wherein said hydrogel composition further includes biologics encapsulated therewithin;

(b) contacting the biochip with an analyte solution, and

(c) detecting the interactions of the biochip with the analyte solution.

23. The bioassay of claim 22 wherein said hydrogel composition is exposed to a second analyte solution as a part of said detecting step.

24. The bioassay of claim 22 wherein said analyte solution contains a marker which binds to said biologic which is a target and wherein the step of detecting comprises detecting the marker bound to the target.

25. The bioassay of claim 24 wherein the marker is capable of fluorescence and wherein the step of detecting the bound target comprises detecting fluorescence from the marker.

26. A method of preparing a hydrogel composition having a biologic encapsulated therein, which method comprises the steps of:

(a) providing an isocyanate-functional hydrogel prepolymer, a biologic, and a crosslinker having at least two thiol groups that will react with said isocyanate-functional hydrogel prepolymer,

(b) mixing said isocyanate-functional hydrogel prepolymer, said biologic and said crosslinker in an aqueous solution, and

(c) maintaining said mixture of step (b) so as to cause said biologic to be encapsulated within a polymerized hydrogel wherein said biologic remains bioactive.


27. The method according to claim 26 wherein said mixture is maintained at a pH of between about 6.5 and about 7.5.

28. The method according to claim 26 wherein said aqueous solution also contains a water-soluble bidentate crosslinker having two different isocyanate-reactive nucleophilic groups.

29. A hydrogel composition having a biologic encapsulated therein, which comprises:



an isocyanate-functional hydrogel prepolymer, a biologic, and a crosslinker having at least two thiol groups,

said isocyanate-functional hydrogel prepolymer having been crosslinked in the presence of said biologic by reaction with said crosslinker in an aqueous solution at physiological conditions and, as a result of said crosslinking, said biologic is encapsulated within a stable polymerized hydrogel in a manner so that said biologic remains bioactive.




X = Polyethyleneoxide or copolymer of polyethyleneoxide and polypropyleneoxide capped with polyisocyanates and lightly crosslinked with polyols

Crosslinking



Continuation of polymerization until all isocyanates are consumed.

FIG 1.





X = Polyethyleneoxide or copolymer of polyethyleneoxide and polypropyleneoxide capped with polyisocyanates and lightly crosslinked with polyols

Y = Polyethyleneoxide or copolymer of polyethyleneoxide and polypropyleneoxide

Z = Polymer or monomer

W = Nucleophile such as amine, hydroxyl or like





 Crosslinking between prepolymers (I and I or I and II) until all isocyanates are consumed.

FIG 2.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US02/10411

A. CLASSIFICATION OF SUBJECT MATTER
 IPC(7) : C12N 5/00
 US CL : 435/182, 180, 382, 395
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 U.S. : 435/182, 180, 382, 395

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 EAST

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,962,280 A (MUKOUYAMA ET AL) 05 October 1999(05.10.99), see entire document.	1-29
A	US 5,849,368 A (HOSTETTLER ET AL) 15 December 1998(15.12.98), see entire document.	1-29

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"B" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 06 September 2002 (06.09.2002)	Date of mailing of the international search report 19 SEP 2002
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230	Authorized officer, Melicia D. Roberts for C. Blaine Lankford Telephone No. 308-0196